229 related articles for article (PubMed ID: 24076775)
1. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma.
Mao TL; Ardighieri L; Ayhan A; Kuo KT; Wu CH; Wang TL; Shih IeM
Am J Surg Pathol; 2013 Sep; 37(9):1342-8. PubMed ID: 24076775
[TBL] [Abstract][Full Text] [Related]
2. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
Guan B; Mao TL; Panuganti PK; Kuhn E; Kurman RJ; Maeda D; Chen E; Jeng YM; Wang TL; Shih IeM
Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
[TBL] [Abstract][Full Text] [Related]
3. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
Werner HM; Berg A; Wik E; Birkeland E; Krakstad C; Kusonmano K; Petersen K; Kalland KH; Oyan AM; Akslen LA; Trovik J; Salvesen HB
Mod Pathol; 2013 Mar; 26(3):428-34. PubMed ID: 23080032
[TBL] [Abstract][Full Text] [Related]
4. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma.
Ayhan A; Mao TL; Seckin T; Wu CH; Guan B; Ogawa H; Futagami M; Mizukami H; Yokoyama Y; Kurman RJ; Shih IeM
Int J Gynecol Cancer; 2012 Oct; 22(8):1310-5. PubMed ID: 22976498
[TBL] [Abstract][Full Text] [Related]
5. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
Wu CH; Mao TL; Vang R; Ayhan A; Wang TL; Kurman RJ; Shih IeM
Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341
[TBL] [Abstract][Full Text] [Related]
6. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
[TBL] [Abstract][Full Text] [Related]
7. Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.
Yen TT; Miyamoto T; Asaka S; Chui MH; Wang Y; Lin SF; Stone RL; Fader AN; Asaka R; Kashima H; Shiozawa T; Wang TL; Shih IM; Tanner EJ
Gynecol Oncol; 2018 Sep; 150(3):426-431. PubMed ID: 30126589
[TBL] [Abstract][Full Text] [Related]
8. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
[TBL] [Abstract][Full Text] [Related]
9. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53.
Ambros RA; Vigna PA; Figge J; Kallakury BV; Mastrangelo A; Eastman AY; Malfetano J; Figge HL; Ross JS
Cancer; 1994 Mar; 73(6):1686-92. PubMed ID: 8156496
[TBL] [Abstract][Full Text] [Related]
10. Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas.
Franceschi T; Durieux E; Morel AP; de Saint Hilaire P; Ray-Coquard I; Puisieux A; Devouassoux-Shisheboran M
Virchows Arch; 2019 Jul; 475(1):85-94. PubMed ID: 30739164
[TBL] [Abstract][Full Text] [Related]
11. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
12. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
[TBL] [Abstract][Full Text] [Related]
13. Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?
Samartzis EP; Samartzis N; Noske A; Fedier A; Caduff R; Dedes KJ; Fink D; Imesch P
Mod Pathol; 2012 Jun; 25(6):885-92. PubMed ID: 22301703
[TBL] [Abstract][Full Text] [Related]
14. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
[TBL] [Abstract][Full Text] [Related]
15. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
16. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.
Allo G; Bernardini MQ; Wu RC; Shih IeM; Kalloger S; Pollett A; Gilks CB; Clarke BA
Mod Pathol; 2014 Feb; 27(2):255-61. PubMed ID: 23887303
[TBL] [Abstract][Full Text] [Related]
17. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
[TBL] [Abstract][Full Text] [Related]
18. ARID1A Regulates Progesterone Receptor Expression in Early Endometrial Endometrioid Carcinoma Pathogenesis.
Asaka S; Liu Y; Yu ZC; Rahmanto YS; Ono M; Asaka R; Miyamoto T; Yen TT; Ayhan A; Wang TL; Shih IM
Mod Pathol; 2023 Feb; 36(2):100045. PubMed ID: 36853791
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical study of endometrial high-grade endometrioid carcinoma with or without a concurrent low-grade component: implications for pathogenetic and survival differences.
Mao TL; Ayhan A; Kuo KT; Lin MC; Tseng LH; Ogawa H
Histopathology; 2015 Oct; 67(4):474-82. PubMed ID: 25648330
[TBL] [Abstract][Full Text] [Related]
20. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.
Wiegand KC; Lee AF; Al-Agha OM; Chow C; Kalloger SE; Scott DW; Steidl C; Wiseman SM; Gascoyne RD; Gilks B; Huntsman DG
J Pathol; 2011 Jul; 224(3):328-33. PubMed ID: 21590771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]